Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 462(7272), 449–460 (2009).
  Medline CASGoogle Scholar
• 2 Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783–801 (2006).
  Medline CASGoogle Scholar
• 3 Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17(4), 338–344 (2005).
  Medline CASGoogle Scholar
• 4 Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 296(5566), 298–300 (2002).
  Medline CASGoogle Scholar
• 5 Murray PJ. NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? Curr. Opin. Immunol. 17(4), 352–358 (2005).
  Medline CASGoogle Scholar
• 6 Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 22(6), 1136–1151 (2004).
  Medline CASGoogle Scholar
• 7 Marshall HD, Urban SL, Welsh RM. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J. Virol. 85(12), 5929–5939 (2011).
  Medline CASGoogle Scholar
• 8 Cho MH, Ahn HJ, Ha HJ et al. Bacillus anthracis capsule activates caspase-1 and induces interleukin-1β release from differentiated THP-1 and human monocyte-derived dendritic cells. Infect. Immun. 78(1), 387–392 (2010).
  Medline CASGoogle Scholar
• 9 Finlay BB, Mcfadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124(4), 767–782 (2006).
  Medline CASGoogle Scholar
• 10 Coombes BK, Valdez Y, Finlay BB. Evasive maneuvers by secreted bacterial proteins to avoid innate immune responses. Curr. Biol. 14(19), R856–R867 (2004).
  Medline CASGoogle Scholar
• 11 Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116(1), 1–27 (2006).
  Medline CASGoogle Scholar
• 12 Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28(23), 3427–3436 (2007).
  Medline CASGoogle Scholar
• 13 Myc A, Kukowska-Latallo JF, Smith DM et al. Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells. Vaccine 31(7), 1072–1079 (2013).
  Medline CASGoogle Scholar
• 14 Thyagarajan R, Arunkumar N, Song W. Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J. Immunol. 170(12), 6099–6106 (2003).
  Medline CASGoogle Scholar
• 15 Dodd CH, Hsu HC, Chu WJ et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 256(1–2), 89–105 (2001).
  Medline CASGoogle Scholar
• 16 Shakweh M, Besnard M, Nicolas V, Fattal E. Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm. 61(1–2), 1–13 (2005).
  Medline CASGoogle Scholar
• 17 Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target. 15(10), 701–713 (2007).
  Medline CASGoogle Scholar
• 18 Amidi M, Romeijn SG, Verhoef JC et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25(1), 144–153 (2007).
  Medline CASGoogle Scholar
• 19 Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 8(2), 151–158 (2009).
  Medline CASGoogle Scholar
• 20 Hailemichael Y, Dai Z, Jaffarzad N et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat. Med. 19(4), 465–472 (2013).• Demonstrates the importance of rate of antigen release in immuno-stimulation.
  Medline CASGoogle Scholar
• 21 Seong S-Y, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4(6), 469–478 (2004).
  Medline CASGoogle Scholar
• 22 Moyano DF, Goldsmith M, Solfiell DJ et al. Nanoparticle hydrophobicity dictates immune response. J. Am. Chem. Soc. 134(9), 3965–3967 (2012).
  Medline CASGoogle Scholar
• 23 Chavez-Santoscoy AV, Roychoudhury R, Pohl NLB, Wannemuehler MJ, Narasimhan B, Ramer-Tait AE. Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using “pathogen-like” amphiphilic polyanhydride nanoparticles. Biomaterials 33(18), 4762–4772 (2012).
  Medline CASGoogle Scholar
• 24 Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41–51 (2007).
  Medline CASGoogle Scholar
• 25 Wang BZ, Xu R, Quan F-S, Kang SM, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010).
  Medline CASGoogle Scholar
• 26 Hatakeyama H, Ito E, Akita H et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 139(2), 127–132 (2009).
  Medline CASGoogle Scholar
• 27 Trumpfheller C, Longhi MP, Caskey M et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J. Intern. Med. 271(2), 183–192 (2012).
  Medline CASGoogle Scholar
• 28 Ahrens ET, Bulte JWM. Tracking immune cells in vivo using magnetic resonance imaging. Nat. Rev. Immunol. 13(10), 755–763 (2013).
  Medline CASGoogle Scholar
• 29 Hobo W, Novobrantseva TI, Fredrix H et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285–297 (2013).
  Medline CASGoogle Scholar
• 30 Akita H, Kogure K, Moriguchi R et al. Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J. Control. Release 149(1), 58–64 (2011).
  Medline CASGoogle Scholar
• 31 Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun. Rev. 7(2), 102–108 (2007).
  Medline CASGoogle Scholar
• 32 Pejawar-Gaddy S, Kovacs J, Barouch D, Chen B, Irvine D. Design of lipid nanoparticle delivery agents for multivalent display of recombinant Env trimers in HIV vaccination. Retrovirology 9(2), 1–1 (2012).
  MedlineGoogle Scholar
• 33 Bershteyn A, Hanson MC, Crespo MP et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J. Control. Release 157(3), 354–365 (2012).
  Medline CASGoogle Scholar
• 34 Chen J, Li Z, Huang H et al. Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int. J. Nanomed. 6, 77–84 (2011).
  Medline CASGoogle Scholar
• 35 Stano A, Van Der Vlies AJ, Martino MM, Swartz MA, Hubbell JA, Simeoni E. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 29(4), 804–812 (2011).
  Medline CASGoogle Scholar
• 36 Uto T, Wang X, Sato K et al. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178(5), 2979–2986 (2007).
  Medline CASGoogle Scholar
• 37 Mukai Y, Yoshinaga T, Yoshikawa M et al. Induction of endoplasmic reticulum–endosome fusion for antigen cross-presentation induced by poly (γ-glutamic acid) nanoparticles. J. Immunol. 187(12), 6249–6255 (2011).
  Medline CASGoogle Scholar
• 38 Kaminski DA, Lee FEH. Revolutions in antibodies against influenza virus. Front. Immunol. 2, 76 (2011).
  MedlineGoogle Scholar
• 39 Kanekiyo M, Wei CJ, Yassine HM et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499(7456), 102–106 (2013).
  Medline CASGoogle Scholar
• 40 Hashemi H, Pouyanfard S, Bandehpour M et al. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza a virus challenge. PLoS ONE 7(9), e45765 (2012).
  Medline CASGoogle Scholar
• 41 Lin AY, Mattos Almeida JP, Bear A et al. Gold nanoparticle delivery of modified cpg stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS ONE 8(5), e63550 (2013).
  Medline CASGoogle Scholar
• 42 Combadière B, Mahé B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 31(2–3), 293–315 (2008).
  MedlineGoogle Scholar
• 43 De Titta A, Ballester M, Julier Z et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl. Acad. Sci. USA USA 110(49), 19902–19907 (2013).
  Medline CASGoogle Scholar
• 44 Stone GW, Barzee S, Snarsky V et al. Nanoparticle-delivered multimeric soluble cd40l dna combined with toll-like receptor agonists as a treatment for melanoma. PLoS ONE 4(10), e7334 (2009).
  MedlineGoogle Scholar
• 45 Sexton A, Whitney PG, Chong S-F et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 3(11), 3391–3400 (2009).
  Medline CASGoogle Scholar
• 46 Wilson JT, Keller S, Manganiello MJ et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7(5), 3912–3925 (2013).
  Medline CASGoogle Scholar
• 47 Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112(1), 26–34 (2006).
  Medline CASGoogle Scholar
• 48 Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12(11), 978–990 (2013).•• Reviews the designs of synthetic vaccines for immunomodulation.
  Medline CASGoogle Scholar
• 49 Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat. Med. 19(12), 1597–1608 (2013).
  Medline CASGoogle Scholar
• 50 Gutierro I, Hernández RM, Igartua M, Gascón AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1–2), 67–77 (2002).
  Medline CASGoogle Scholar
• 51 Zhu Q, Talton J, Zhang G, Cunningham T, Berzofsky Jay A. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat. Med. 18(8), 1 (2012).
  MedlineGoogle Scholar
• 52 Bivas-Benita M, Laloup M, Versteyhe S et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int. J. Pharm. 266(1–2), 17–27 (2003).
  Medline CASGoogle Scholar
• 53 Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5(4), 387–391 (1999).
  Medline CASGoogle Scholar
• 54 Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42(12), 821–826 (1990).
  Medline CASGoogle Scholar
• 55 Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50(1–2), 81–106 (2001).
  Medline CASGoogle Scholar
• 56 Gupta PN, Vyas SP. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B. Biointerfaces 82(1), 118–125 (2011).
  Medline CASGoogle Scholar
• 57 Garinot M, Fiévez V, Pourcelle V et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120(3), 195–204 (2007).
  Medline CASGoogle Scholar
• 58 Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430–445 (2001).
  Medline CASGoogle Scholar
• 59 Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148–158 (2006).
  Medline CASGoogle Scholar
• 60 Noh YW, Hong JH, Shim SM et al. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew. Chem. Int. Ed. 52(30), 7684–7689 (2013).
  Medline CASGoogle Scholar
• 61 Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50(1), 147–160 (2000).
  Medline CASGoogle Scholar
• 62 Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE 6(3), e17642 (2011).
  Medline CASGoogle Scholar
• 63 Bivas-Benita M, Van Meijgaarden KE, Franken KLMC et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22(13–14), 1609–1615 (2004).
  Medline CASGoogle Scholar
• 64 Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by streptococcus pneumoniae. Clin. Vaccine Immunol. 18(1), 75–81 (2011).
  Medline CASGoogle Scholar
• 65 Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. Intranasal delivery of chitosan–DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22(27–28), 3603–3612 (2004).
  Medline CASGoogle Scholar
• 66 Taki AC, Kikidopoulos N, Baird FJ, Smooker PM. Improving the immunogenicity of DNA vaccines: a nano-sized task? In: In DNA Vaccines: Types, Advantages and Limitations. Donnelly EC, Dixon AM (Eds). Nova Science, NY, USA, 153–181 (2012).
  Google Scholar
• 67 Li AV, Moon JJ, Abraham W et al. Generation of effector memory T cell–based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5(204), 204ra130 (2013).
  MedlineGoogle Scholar
• 68 Yang M, Lai SK, Wang YY et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. 50(11), 2597–2600 (2011).
  Medline CASGoogle Scholar
• 69 Swartz MA, Hubbell JA, Reddy ST. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin. Immunol. 20(2), 147–156 (2008).
  Medline CASGoogle Scholar
• 70 Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5, 617–628 (2005).
  Medline CASGoogle Scholar
• 71 Reddy ST, Van Der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotech. 25(10), 1159–1164 (2007).• Demonstrates the role of nanoparticle size and surface in lymph node migration.
  Medline CASGoogle Scholar
• 72 Videira MA, Gano L, Santos C, Neves M, Almeida AJ. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J. Microencaps. 23(8), 855–862 (2006).
  Medline CASGoogle Scholar
• 73 Videira MA, Botelho MF, Santos AC, Gouveia LF, Pedroso De Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 10(8), 607–613 (2002).
  Medline CASGoogle Scholar
• 74 Bargoni A, Cavalli R, Caputo O, Fundarò A, Gasco M, Zara G. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 15(5), 745–750 (1998).
  Medline CASGoogle Scholar
• 75 Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35(2), 814–824 (2014).
  Medline CASGoogle Scholar
• 76 Liu H, Moynihan KD, Zheng Y et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507(7493), 519–522 (2014).
  Medline CASGoogle Scholar
• 77 Gunzer M. Vaccine adjuvants: tailor-made mast-cell granules. Nat. Mater. 11(3), 181–182 (2012).
  Medline CASGoogle Scholar
• 78 Kunder CA, John ALS, Li GJ et al. Mast cell-derived particles deliver peripheral signals to remote lymph nodes. J. Exp. Med. 206(11), 2455–2467 (2009).
  Medline CASGoogle Scholar
• 79 Romani N, Flacher V, Tripp CH, Sparber F, Ebner S, Stoitzner P. Targeting skin dendritic cells to improve intradermal vaccination. In: Intradermal Immunization. Teunissen MBM (Ed.). Springer Berlin Heidelberg, 113–138 (2012).
  Google Scholar
• 80 Matsuo K, Hirobe S, Okada N, Nakagawa S. Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine 31(19), 2403–2415 (2013).
  Medline CASGoogle Scholar
• 81 Zhan X, Tran KK, Shen H. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. Mol. Pharm. 9(12), 3442–3451 (2012).
  Medline CASGoogle Scholar
• 82 Mittal A, Raber AS, Schaefer UF et al. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 31(34), 3442–3451 (2013).
  Medline CASGoogle Scholar
• 83 Jain S, Yap WT, Irvine DJ. Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and cpg oligonucleotide delivery to antigen-presenting cells. Biomacromolecules 6(5), 2590–2600 (2005).
  Medline CASGoogle Scholar
• 84 Elamanchili P, Lutsiak CME, Hamdy S, Diwan M, Samuel J. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 30(4), 378–395 (2007).
  Medline CASGoogle Scholar
• 85 Wang X, Uto T, Akagi T, Akashi M, Baba M. Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J. Med. Virol. 80(1), 11–19 (2008).
  Medline CASGoogle Scholar
• 86 Faisal SM, Chen JW, Mcdonough SP, Chang CF, Teng CH, Chang YF. Immunostimulatory and antigen delivery properties of liposomes made up of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses. Vaccine 29(13), 2381–2391 (2011).
  Medline CASGoogle Scholar
• 87 Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposome-anchored anti-cd137 + il-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 73(5), 1547–1558 (2013).
  Medline CASGoogle Scholar
• 88 Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. USA 109(4), 1080–1085 (2012).
  Medline CASGoogle Scholar
• 89 Ilyinskii PO, Roy CJ, O'neil CP et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 32(24), 2882–2895 (2014).
  Medline CASGoogle Scholar
• 90 Keijzer C, Slütter B, Van Der Zee R, Jiskoot W, Van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 6(11), e26684 (2011).
  Medline CASGoogle Scholar
• 91 Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC. Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol. Pharm. 9(1), 81–90 (2011).
  MedlineGoogle Scholar
• 92 Pattani A, Patravale VB, Panicker L, Potdar PD. Immunological effects and membrane interactions of chitosan nanoparticles. Mol. Pharm. 6(2), 345–352 (2009).
  Medline CASGoogle Scholar
• 93 Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 62(1), 3–11 (2010).
  Medline CASGoogle Scholar
• 94 Petersen LK, Ramer-Tait AE, Broderick SR et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 32(28), 6815–6822 (2011).•• Systematically illustrates the molecular designs of nanoparticle for pathogen mimicking vaccination.
  Medline CASGoogle Scholar
• 95 Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert Opin. Biol. Ther. 4(12), 1953–1962 (2004).
  Medline CASGoogle Scholar
• 96 Salman HH, Irache JM, Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 27(35), 4784–4790 (2009).
  Medline CASGoogle Scholar
• 97 Yang M, Flavin K, Kopf I et al. Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and nlrp3 inflammasome activation. Small 9(24), 4194–4206 (2013).
  Medline CASGoogle Scholar
• 98 Yazdi AS, Guarda G, Riteau N et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl. Acad. Sci. USA 107(45), 19449–19454 (2010).
  Medline CASGoogle Scholar
• 99 Demento SL, Eisenbarth SC, Foellmer HG et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27(23), 3013–3021 (2009).
  Medline CASGoogle Scholar
• 100 Petersen LK, Xue L, Wannemuehler MJ, Rajan K, Narasimhan B. The simultaneous effect of polymer chemistry and device geometry on the in vitro activation of murine dendritic cells. Biomaterials 30(28), 5131–5142 (2009).
  Medline CASGoogle Scholar
• 101 Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095–1107 (2010).
  Medline CASGoogle Scholar
• 102 Kreuter J, Berg U, Liehl E, Soliva M, Speiser PP. Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants. Vaccine 4(2), 125–129 (1986).
  Medline CASGoogle Scholar
• 103 Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20(10), 1006–1010 (2002).
  Medline CASGoogle Scholar
• 104 Heo MB, Lim YT. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials 35(1), 590–600 (2014).
  Medline CASGoogle Scholar
• 105 Heo MB, Cho MY, Lim YT. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells. Acta Biomater. 10(5), 2169–2176 (2014).
  Medline CASGoogle Scholar
• 106 Kim JH, Noh YW, Heo MB, Cho MY, Lim YT. Multifunctional hybrid nanoconjugates for efficient in vivo delivery of immunomodulating oligonucleotides and enhanced antitumor immunity. Angew. Chem. Int. Ed. 51(38), 9670–9673 (2012).
  Medline CASGoogle Scholar
• 107 Alshamsan A, Haddadi A, Hamdy S et al. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. 7(5), 1643–1654 (2010).
  Medline CASGoogle Scholar
• 108 Massagué J. TGFβ in cancer. Cell 134(2), 215–230 (2008).
  Medline CASGoogle Scholar
• 109 Yang L, Pang Y, Moses HL. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31(6), 220–227 (2010).
  Medline CASGoogle Scholar
• 110 Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8(4), 3636–3645 (2014).
  Medline CASGoogle Scholar
• 111 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26(1), 677–704 (2008).
  Medline CASGoogle Scholar
• 112 Wei M, Chen N, Li J et al. Polyvalent immunostimulatory nanoagents with self-assembled cpg oligonucleotide-conjugated gold nanoparticles. Angew. Chem. Int. Ed. 51(5), 1202–1206 (2012).
  Medline CASGoogle Scholar
• 113 Shukoor MI, Natalio F, Tahir MN et al. Pathogen-mimicking MnO nanoparticles for selective activation of the TLR9 pathway and imaging of cancer cells. Adv. Funct. Mater. 19(23), 3717–3725 (2009).
  CASGoogle Scholar
• 114 Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37(20), 2754–2794 (1998).
  MedlineGoogle Scholar
• 115 Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J. Immunol. 144(5), 1640–1645 (1990).
  Medline CASGoogle Scholar
• 116 Watson DS, Platt VM, Cao L, Venditto VJ, Szoka FC. Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice. Clin. Vaccine Immunol. 18(2), 289–297 (2011).
  Medline CASGoogle Scholar
• 117 Lee I-H, Kwon HK, An S et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew. Chem. Int. Ed. 51(35), 8800–8805 (2012).
  Medline CASGoogle Scholar
• 118 Chen YS, Hung YC, Lin W-H, Huang GS. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21(19), 195101 (2010).
  MedlineGoogle Scholar
• 119 Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871–3878 (2007).
  Medline CASGoogle Scholar
• 120 Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a plasmodium vivax malaria vaccine. PLoS ONE 7(2), e31472 (2012).
  Medline CASGoogle Scholar
• 121 Ashwood P, Thompson RPH, Powell JJ. Fine particles that adsorb lipopolysaccharide via bridging calcium cations may mimic bacterial pathogenicity towards cells. Exp. Biol. Med. 232(1), 107–117 (2007).
  CASGoogle Scholar
• 122 Akagi T, Kim H, Akashi M. pH-Dependent disruption of erythrocyte membrane by amphiphilic poly(amino acid) nanoparticles. J. Biomater. Sci. Polym. Ed. 21(3), 315–328 (2010).
  Medline CASGoogle Scholar
• 123 Shen H, Ackerman AL, Cody V et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117(1), 78–88 (2006).
  Medline CASGoogle Scholar
• 124 Rosalia R, Silva A, Camps M et al. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. Cancer Immunol. Immunother. 62(7), 1161–1173 (2013).
  Medline CASGoogle Scholar
• 125 Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16(10), 1217–1226 (2002).
  Medline CASGoogle Scholar
• 126 Sneh-Edri H, Likhtenshtein D, Stepensky D. Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol. Pharm. 8(4), 1266–1275 (2011).
  Medline CASGoogle Scholar
• 127 Han R, Zhu J, Yang X, Xu H. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J. Biomed. Mater. Res. Part A 96A(1), 142–149 (2011).
  CASGoogle Scholar
• 128 Li P, Luo Z, Liu P et al. Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses. J. Control. Release 168(3), 271–279 (2013).
  Medline CASGoogle Scholar
• 129 Luo Z, Li P, Deng J et al. Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy. J. Control. Release 170(2), 259–267 (2013).
  Medline CASGoogle Scholar
• 130 Kwon YJ, Standley SM, Goh SL, Fréchet JMJ. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control. Release 105(3), 199–212 (2005).
  Medline CASGoogle Scholar
• 131 Hirosue S, Kourtis IC, Van Der Vlies AJ, Hubbell JA, Swartz MA. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 28(50), 7897–7906 (2010).
  Medline CASGoogle Scholar
• 132 Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat. Nanotechnol. 6(10), 645–650 (2011).
  Medline CASGoogle Scholar
• 133 Shen SS, Yang YW. Antigen delivery for cross priming via the emulsion vaccine adjuvants. Vaccine 30(9), 1560–1571 (2012).
  Medline CASGoogle Scholar
• 134 Horth M, Lambrecht B, Khim MCL et al. Theoretical and functional analysis of the SIV fusion peptide. EMBO J. 10(10), 2747–2755 (1991).
  Medline CASGoogle Scholar
• 135 Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56(1), 365–394 (1987).
  Medline CASGoogle Scholar
• 136 Marsh M, Helenius A. Virus entry into animal cells. In: Advances In Virus Research. Karl Maramorosch FaM, Aaron JS (Eds). Academic Press, UT, USA, 107–151 (1989).
  Google Scholar
• 137 Sasaki K, Kogure K, Chaki S et al. An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives. Anal. Bioanal. Chem. 391(8), 2717–2727 (2008).
  Medline CASGoogle Scholar
• 138 Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418–1423 (2005).
  Medline CASGoogle Scholar
• 139 Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 3(3), 343–355 (2008).
  CASGoogle Scholar
• 140 Klechevsky E, Flamar A-L, Cao Y et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 116(10), 1685–1697 (2010).
  Medline CASGoogle Scholar
• 141 Benitez-Ribas D, Adema GJ, Winkels G et al. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake. J. Exp. Med. 203(7), 1629–1635 (2006).
  Medline CASGoogle Scholar
• 142 Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Chapter eight - Targeting nanoparticles to dendritic cells for immunotherapy. In: Methods In Enzymology. Nejat D (Ed.). Academic Press, UT, USA, 143–163 (2012).• Overviews the rationale for nanoparticle mediated vaccine delivery to dendritic cells.
  Google Scholar
• 143 Tel J, Sittig SP, Blom RaM et al. Targeting Uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type i IFN secretion. J. Immunol. 191(10), 5005–5012 (2013).
  Medline CASGoogle Scholar
• 144 Cruz LJ, Tacken PJ, Fokkink R et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144(2), 118–126 (2010).
  Medline CASGoogle Scholar
• 145 Yu B, Mao Y, Bai LY et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121(1), 136–147 (2013).
  Medline CASGoogle Scholar
• 146 Mao Y, Wang J, Zhao Y et al. A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery. Nanomed. Nanotechnol. Biol. Med. 10(2), 393–400 (2014).
  CASGoogle Scholar
• 147 Gunn J, Wallen H, Veiseh O et al. A multimodal targeting nanoparticle for selectively labeling T cells. Small 4(6), 712–715 (2008).
  Medline CASGoogle Scholar
• 148 Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J. Control. Release 172(2), 426–435 (2013).
  Medline CASGoogle Scholar
• 149 Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm. 8(1), 143–152 (2010).
  MedlineGoogle Scholar
• 150 Aspord C, Laurin D, Janier MF et al. Paramagnetic nanoparticles to track and quantify in vivo immune human therapeutic cells. Nanoscale 5(23), 11409–11415 (2013).
  Medline CASGoogle Scholar
• 151 Cho NH, Cheong TC, Min JH et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nano. 6(10), 675–682 (2011).
  Medline CASGoogle Scholar
• 152 Boutry S, Laurent S, Vander Elst L, Muller RN. Cellular magnetic labeling with iron oxide nanoparticles. In: Nanoplatform-Based Molecular Imaging. John Wiley & Sons, Inc., NJ, USA, 309–331 (2011).
  Google Scholar
• 153 Wilhelm C, Gazeau F. Universal cell labelling with anionic magnetic nanoparticles. Biomaterials 29(22), 3161–3174 (2008).
  Medline CASGoogle Scholar
• 154 Wilhelm C, Lavialle F, Péchoux C, Tatischeff I, Gazeau F. Intracellular trafficking of magnetic nanoparticles to design multifunctional biovesicles. Small 4(5), 577–582 (2008).
  Medline CASGoogle Scholar
• 155 Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, De Vries IJM. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 31(27), 7070–7077 (2010).
  Medline CASGoogle Scholar
• 156 Lim YT, Cho MY, Kang JH et al. Perfluorodecalin/[InGaP/ZnS quantum dots] nanoemulsions as ¹⁹F MR/optical imaging nanoprobes for the labeling of phagocytic and nonphagocytic immune cells. Biomaterials 31(18), 4964–4971 (2010).
  Medline CASGoogle Scholar
• 157 Kim HM, Lee H, Hong KS et al. Synthesis and high performance of magnetofluorescent polyelectrolyte nanocomposites as mr/near-infrared multimodal cellular imaging nanoprobes. ACS Nano 5(10), 8230–8240 (2011).
  Medline CASGoogle Scholar
• 158 Kim HM, Noh YW, Park HS et al. Self-fluorescence of chemically crosslinked mri nanoprobes to enable multimodal imaging of therapeutic cells. Small 8(5), 666–670 (2012).
  Medline CASGoogle Scholar
• 159 Pittet MJ, Swirski FK, Reynolds F, Josephson L, Weissleder R. Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat. Protocols 1(1), 73–79 (2006).
  Medline CASGoogle Scholar
• 160 Bhirde A, Xie J, Swierczewska M, Chen X. Nanoparticles for cell labeling. Nanoscale 3(1), 142–153 (2011).
  Medline CASGoogle Scholar
• 161 Ottobrini L, Martelli C, Trabattoni D, Clerici M, Lucignani G. In vivo imaging of immune cell trafficking in cancer. Eur. J. Nucl. Med. Mol. Imag. 38(5), 949–968 (2011).
  MedlineGoogle Scholar
• 162 Smirnov P, Lavergne E, Gazeau F et al. In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn. Reson. Med. 56(3), 498–508 (2006).
  Medline CASGoogle Scholar
• 163 Fahmy T, Fong P, Park J, Constable T, Saltzman WM. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J. 9(2), E171–E180 (2007).
  MedlineGoogle Scholar
• 164 Noh YW, Jang YS, Ahn KJ, Lim YT, Chung BH. Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials 32(26), 6254–6263 (2011).
  Medline CASGoogle Scholar
• 165 Hu CMJ, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 8(12), 933–938 (2013).
  Medline CASGoogle Scholar
• 166 Soenen SJ, Rivera-Gil P, Montenegro JM, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 6(5), 446–465 (2011).
  CASGoogle Scholar
• 167 Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4(7), 411–414 (2009).
  Medline CASGoogle Scholar
• 168 Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem. Soc. Rev. 42(12), 5552–5576 (2013).
  Medline CASGoogle Scholar